SLC5A2 and fatty liver disease: The objective of this meta-analysis is to evaluate the effectiveness of sodium–glucose cotransporter-2 (SGLT-2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease.